Navigation Links
Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease
Date:6/9/2011

re, especially at the beginning of treatment, due to the general risk of orthostatic hypotension associated with dopaminergic therapy.

Neupro® has been associated with somnolence episodes of sudden sleep onset episodes. Patients treated with dopamine agonists including Neupro®, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality.

Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore it is recommended to taper treatment.

Neupro® contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people.

Hallucinations have been reported, and patients should be informed that hallucinations can occur.

Cases of cardiopulmonary fibrotic complications have been reported in some patients treated with ergot-derived dopaminergic agents. Neuroleptics given as antiemetic should not be given to patients taking dopamine agonists. Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.

External heat, from any source should not be applied to the area of the patch. Exposure of a skin rash or irritation to direct sunlight could lead to changes in the skin color. If a generalized skin reaction (e.g. allergic rash) associated with the use of Neupro® is observed, Neupro® should be discontinued.

Caution is advised when treating patients with severe hepatic impairment or acute worsening of renal function, a dose reduction might be needed.

The incidence of some dopaminergic adverse events, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa. This should be considered when prescribi
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- The North American spine surgery devices market is ... U.S. having the maximum market share. This region is ... The market, by product type, encompasses spinal ... devices, non-fusion implant devices, and spine bone stimulators devices. ... is the largest and fastest-growing segment. Key players ...
(Date:6/3/2015)...  Actavis plc (NYSE: ACT ), a leading global ... and President of Actavis, will provide an overview and update ... Global Healthcare Conference in Rancho Palos Verdes, Calif. ... The presentation will take place on Wednesday, June ... Resort, Rancho Palos Verdes, Calif.  To ...
(Date:6/3/2015)... , June 02, 2015 Research ... addition of the "The Future of Pharmaceutical ... As they are in a desperate need to ... low cost, drug companies have been increasingly utilizing ... their productivity while constantly streamlining their internal operation. ...
Breaking Medicine Technology:Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... MOUNTAIN VIEW, Calif. , Jan. 28 Omnicell, Inc. (Nasdaq: ... facilities, today announced results for its fourth quarter and year ended ... fourth quarter of 2009 was $54.7 million , up $0.7 ... $7.4 million or 11.9% from the fourth quarter of 2008. ...
... , SAN DIEGO , Jan. 28 ... Phase II clinical trial evaluating CTS-1027 in combination with pegylated ... activity, safety and tolerability of the triple combination will be ... is a significant unmet medical need in HCV patients who ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:6/3/2015)... Accountable care organizations (ACOs) are increasingly partnering ... worries that these product types were too similar to ... that product-based ACOs will continue to grow in size ... June issue of Atlantic Information Services, Inc.’s (AIS) AIS’s ... that the backlash from HMOs seems to be fading ...
(Date:6/3/2015)... Save On Medical ( http://www.saveonmedical.com ) ... shopping for health care procedures easier for patients on ... look and makes it easier to compare the prices ... , Now, when patients search for the procedure they ... they can see the provider’s price and Docometer quality ...
(Date:6/3/2015)... The National Resident Matching Program Board of Directors ... of Medical Education at the University of California, San Diego ... , “It is an honor to assume the ... Dr. Savoia. “NRMP’s goal is to provide a fair, ... programs, and I welcome the opportunity to guide the organization ...
(Date:6/3/2015)... 2015 Dr. Steven Reisman, a nationally recognized ... ( http://www.newyorkcardiac.com ) located in NYC, announced today the expansion ... practice. In most cases, depending on the level of care ... call, they will be seen by a cardiologist that same ... cardiologist is to ensure that people who have an urgent ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 A ... will be honored with a Global Inspire Award at ... recognizes the organization’s outstanding volunteers for their leadership, level ... scale. , The recipients of the Author(s) ... group of authors whose article has made a significant ...
Breaking Medicine News(10 mins):Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 2Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 3Health News:Save On Medical Launches New Mobile-Optimized Website 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4
... Jan. 7 The following is a statement by ... of the State address put forth recommendations on a ... care and financial security of New Yorkers of all ... Family Health Plus Program to 200 percent of the ...
... Whether low levels would work for ER patients with ... -- Going to the world,s most elevated natural laboratory, ... medical rules about the amount of oxygen needed by ... people can tolerate extremely low levels of oxygen, much ...
... known as Emily,s Law, has received Governor Ted Strickland,s ... of Ohio. Named after Emily Jerry, Emily,s Law will ... law, which was originally sponsored by Senator Tim Grendell, ... Association. Emily,s Story , Emily Jerry died at ...
... Provide Support and Convenience CARLSBAD, Calif., Jan. 7 ... a new on-line service for physicians and patients ... products. The new Web site, www.skinmedica.com , ... while offering the convenience of on-line information and ...
... WESTCHESTER, Ill., Jan. 7 BrainLAB, Inc., ... medical treatments,announces a new, customer-focused sales and ... growth and an expanding product,portfolio. , ... and support structures, customers will benefit,from a ...
... AR, AZ, CO, FL, LA, NM and TXBOISE, Idaho, ... its Albertsons Rx-tra Savings prescription discount program ... a 90-day supply of over 500 generic drugs. ... its formulary of over 500 drugs that are already ...
Cached Medicine News:Health News:Study of Everest Climbers Questions Oxygen Use 2Health News:Study of Everest Climbers Questions Oxygen Use 3Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 2Health News:Emily's Law for Regulating Pharmacy Technicians Signed by Ohio Governor 3Health News:SkinMedica Launches On-Line Service for Physician Partners 2Health News:BrainLAB, Inc. Announces New, Streamlined Surgery Business Division 2Health News:Albertson's LLC Launches $10.99 for 90-day Supply of Generic Drugs as Part of Rx-tra Savings Prescription Discount Program 2
... IgG Test is an ELISA ... of IgG to Varicella Zoster ... used as,an aid to determine ... status may be determined using ...
The ImmunoWELL Thyroglobulin IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroglobulin in serum and is used as an aid ...
... Screening Panel 4 is an enzyme ... detection of autoantibodies against various specific ... and Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Medicine Products: